| __timestamp | Genmab A/S | Rhythm Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 79529000 | 1213000 |
| Thursday, January 1, 2015 | 91224000 | 3425000 |
| Friday, January 1, 2016 | 102413000 | 6311000 |
| Sunday, January 1, 2017 | 146987000 | 9518000 |
| Monday, January 1, 2018 | 213695000 | 28080000 |
| Tuesday, January 1, 2019 | 342000000 | 36550000 |
| Wednesday, January 1, 2020 | 661000000 | 46125000 |
| Friday, January 1, 2021 | 1283000000 | 68486000 |
| Saturday, January 1, 2022 | 2676000000 | 92032000 |
| Sunday, January 1, 2023 | 3297000000 | 117532000 |
| Monday, January 1, 2024 | 3790000000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical industry, understanding the financial dynamics of companies is crucial. This chart offers a fascinating glimpse into the Selling, General, and Administrative (SG&A) expenses of Genmab A/S and Rhythm Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Genmab A/S has seen a staggering increase in SG&A expenses, growing by over 4,000%, from approximately $80 million in 2014 to nearly $3.3 billion in 2023. This reflects Genmab's aggressive expansion and investment in its operational capabilities.
In contrast, Rhythm Pharmaceuticals, Inc. has experienced a more modest growth in SG&A expenses, increasing by about 9,600% from $1.2 million in 2014 to $117 million in 2023. This indicates a steady scaling of operations as the company navigates its niche market. The data underscores the diverse strategies these companies employ in managing their operational costs.
Eli Lilly and Company vs Genmab A/S: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of AstraZeneca PLC and Rhythm Pharmaceuticals, Inc.
Vertex Pharmaceuticals Incorporated vs Genmab A/S: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Genmab A/S and Blueprint Medicines Corporation
Genmab A/S vs Walgreens Boots Alliance, Inc.: SG&A Expense Trends
Genmab A/S vs Travere Therapeutics, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Rhythm Pharmaceuticals, Inc.
Bio-Techne Corporation vs Rhythm Pharmaceuticals, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Halozyme Therapeutics, Inc. and Rhythm Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Lantheus Holdings, Inc. or Rhythm Pharmaceuticals, Inc.
Comparing SG&A Expenses: Rhythm Pharmaceuticals, Inc. vs MannKind Corporation Trends and Insights
Cost Management Insights: SG&A Expenses for Rhythm Pharmaceuticals, Inc. and MiMedx Group, Inc.